Click here to joinour Electronic Communications.
Click here to view our presentations at SITC 33rd Annual Meeting SITC 2018
Results from a Phase I dose escalation trial (TACTImel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
A multicenter, phase II study in patients with first line NSCLC, or recurrent PD-X refractory NSCLC or with recurrent HNSCC receiving Eftilagimod Alpha in combination with Pembrolizumab (TACTI-002)
Two ACTive immunotherapies in melanoma (TACTI-mel):results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab
Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”
Download "Ladenburg 2018 HC Conference Immutep Presentation"
Listen to the webcast “Immutep Newsmakers Presentation”
Download "Newsmaker Immutep Corporate Presentation"
LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?
LAG-3: Identification & Validation Of Next Generation Checkpoint Pathway
Combination Strategies for LAG-3Ig (IMP321) With Either Chemotherapy or Anti-PD-1 Therapy